SARS-CoV-2; COVID-19; prevalence; antibody testing; SARS-CoV-2 IgG; SARS-CoV-2 IgM; seroepidemiologic studies; viral antibodies; coronavirus infections; pandemics; serologic tests


Respiratory Tract Diseases | Virus Diseases


Background: SARS-CoV-2 antibody testing shows the prevalence of COVID-19 disease in different communities and has epidemiological significance.

Methods: SARS-CoV-2 IgM and IgG were tested in 319 patients, staff and visitors of a primary care clinic in Las Vegas, NV on a continuous as-requested basis.

Results: Prevalence of SARS-CoV-2 antibodies was 3.76% in a primary care office in Las Vegas, NV. Positivity of IgM was 0.31% and IgG 3.44%. The most common symptoms reported amongst those who tested positive were cough, shortness of breath and loss of smell and taste. The most common comorbidities included hypertension, chronic lung disease, seasonal allergies, and type 2 diabetes mellitus, in that order.

Conclusion: Prevalence was 2.3% in Washoe County, NV in June 2020 and 3.76% in Clark County, NV in April–June 2020. This has important implications for heavily populated urban areas.